Parsaik AK, Singh B, Roberts RO, Pankratz S, Edwards KK, Geda YE, Gharib H, Boeve BF, Knopman DS, Petersen RC. Hypothyroidism and Risk of Mild Cognitive Impairment in Elderly PersonsA Population-Based Study. JAMA Neurol. 2014;71(2):201-207. doi:10.1001/jamaneurol.2013.5402
An association of clinical and subclinical hypothyroidism with mild cognitive impairment (MCI) has not been established.
To evaluate the association of clinical and subclinical hypothyroidism with MCI in a large population-based cohort.
Design, Setting, and Participants
A cross-sectional, population-based study was conducted in Olmsted County, Minnesota. Randomly selected participants were aged 70 to 89 years on October 1, 2004, and were without documented prevalent dementia. A total of 2050 participants were evaluated and underwent in-person interview, neurologic evaluation, and neuropsychological testing to assess performance in memory, attention/executive function, and visuospatial and language domains. Participants were categorized by consensus as being cognitively normal, having MCI, or having dementia according to published criteria. Clinical and subclinical hypothyroidism were ascertained from a medical records linkage system.
Main Outcomes and Measures
Association of clinical and subclinical hypothyroidism with MCI.
Among 1904 eligible participants, the frequency of MCI was 16% in 1450 individuals with normal thyroid function, 17% in 313 persons with clinical hypothyroidism, and 18% in 141 individuals with subclinical hypothyroidism. After adjusting for covariates (age, educational level, sex, apolipoprotein E ε4, depression, diabetes mellitus, hypertension, stroke, body mass index, and coronary artery disease) we found no significant association between clinical or subclinical hypothyroidism and MCI (odds ratio [OR], 0.99 [95% CI, 0.66-1.48] and 0.88 [0.38-2.03], respectively). No effect of sex interaction was seen on these effects. In stratified analysis, the odds of MCI with clinical and subclinical hypothyroidism among men was 1.02 (95% CI, 0.57-1.82) and 1.29 (0.68-2.44) and, among women, was 1.04 (0.66-1.66) and 0.86 (0.37-2.02), respectively.
Conclusions and Relevance
In this population-based cohort of elderly people, neither clinical nor subclinical hypothyroidism was associated with MCI. Our findings need to be validated in a separate setting using the published criteria for MCI and confirmed in a longitudinal study.
Growing evidence has linked the alteration in the endocrine system, in particular thyroid dysfunction, to the pathogenesis of Alzheimer disease (AD) and other dementias.1 Therefore, measurement of serum thyroid-stimulating hormone (TSH) has become the standard screening test during the evaluation of patients with cognitive decline.2 Subclinical hypothyroidism, which is defined biochemically as a normal serum free thyroxine concentration in the presence of an elevated TSH concentration, has a controversial association with cognitive impairment. Although many investigators have reported positive associations between memory impairment and subclinical hypothyroidism,3- 7 others have reported better performance in some areas of cognitive function among patients with decreased thyroid function8 or no association.9- 15
Similarly, the association between clinical hypothyroidism and cognitive impairment is controversial and has been an issue for debate. Some studies have reported a positive association,16- 19 and others found no relationship.20- 24 This inconsistency in the association across studies could result from various reasons, including differing diagnostic criteria for cognitive impairment or hypothyroidism, measurement instruments, and small sample sizes. Moreover, none of the studies specifically looked for an association between hypothyroidism and mild cognitive impairment (MCI).
The MCI phase of the cognitive trajectory from normal aging to dementia has minimal clinical features with none or minimal functional impairment and can be identified by the recently published National Institute on Aging and Alzheimer’s Association criteria.25- 29 Currently approved treatments for AD (eg, cholinesterase inhibitors, memantine) do not provide a “cure” in fully symptomatic patients, partly because the treatments are administered too late in the disease process. Therefore, recognizing the earliest stage of the pathophysiologic process of cognitive impairment and understanding the etiologic association with thyroid dysfunction is important. Early interventions focused on treating the underlying sources of cognitive decline may improve cognition or at least prevent further progression.27
The main objective of our study was to investigate the association of subclinical and clinical hypothyroidism (treated and untreated) with MCI in a population-based cohort of elderly persons from Olmsted County, Minnesota. We hypothesized that clinical and subclinical hypothyroidism are the important risk factors for MCI.
Our study was approved by the institutional review boards of Mayo Clinic and Olmsted County Medical Center. All individuals signed an informed consent form to participate in the study and only those who provided authorization to review their medical records for research purposes were included. Patients received financial compensation for their time. In 2004, the Mayo Clinic Olmsted Study of Aging (also known as the Alzheimer Disease Patient Registry) used the resources of the Rochester Epidemiology Project to establish a population-based cohort of individuals aged 70 to 89 years on October 1, 2004. The detailed study design and participant recruitment have been described in a previous report.30 In brief, using Rochester Epidemiology Project resources, we identified a total of 9953 persons between the ages of 70 and 89 years, and a sample of 5233 was randomly selected for recruitment. Of the 5233 selected individuals, 402 had dementia at baseline, 263 died before they could be contacted, 56 were in hospice care, and 114 could not be contacted. Of the 4398 remaining eligible persons, 2719 participated in the baseline evaluation. The baseline evaluation was conducted from October 1, 2004, through July 31, 2007, and consisted of a telephone interview with 669 individuals and in-person full participation by 2050 people.30
Each participant was initially evaluated by a nurse or study coordinator to assess the demographics, medical comorbidities, and memory questionnaires administered. The Clinical Dementia Rating scale31 and Functional Activities Questionnaires32 were administered to an informant.
Participants also underwent extensive psychometric testing to assess performance in memory, executive function, language, and visuospatial skills domains. Psychometric tests involved 9 cognitive tests: Logical Memory–II (delayed recall) and Visual Reproduction–II (delayed recall) from the Wechsler Memory Scale–Revised and the Auditory Verbal Learning Test for memory domains,33,34 Trail Making Test B, and Digit Symbol Substitution from Wechsler Adult Intelligence Scale–Revised for executive function35,36; Boston Naming Test and Category Fluency Test37,38 for language; and Picture Completion and Block Design from the Wechsler Adult Intelligence Scale–Revised for visuospatial skills.36 Each of the raw test scores was transformed to age-adjusted scores using the normative data from the Mayo’s Older Americans Normative Studies and scaled to a mean (SD) of 10 (3).39 Age-adjusted scaled scores in each domain were summed to obtain the domains score, and impairment in a domain was determined by comparing the scores with the mean (SD) of the population norms. Cognitive impairment was considered possible if the mean score was 1.0 SD or more below the mean when compared with normative data derived from Olmsted County.39 A neurologic evaluation of each participant was performed by a physician or neurologist and included administration of the Short Test of Mental Status,40 a medical history review, and a detailed neurologic examination. The final diagnosis of cognitive impairment in a domain was based on the consensus agreement between the evaluating physician, nurse, and neuropsychologist after considering other important information, such as educational level, occupation, visual impairment, and hearing deficiency.41
The following published criteria were used to make the diagnosis of MCI: memory concern raised by the research participants during the nurse interview, by informants (Clinical Dementia Rating scale), coordinators, or examining physicians; impairment in 1 or more of the 4 cognitive domains from the cognitive battery; essentially normal functional activities from the Clinical Dementia Rating scale and Functional Activities Questionnaires; and absence of dementia.42 Individuals with MCI were further divided into amnestic MCI if the memory domain was impaired and nonamnestic MCI if the memory domain was not impaired but at least 1 memory domain was impaired. Dementia was diagnosed based on Diagnostic and Statistical Manual (Fourth Edition) criteria.43 Persons who did not meet criteria for MCI or dementia and performed within the normal cognitive range of the normative data for this community39 were considered cognitively normal.
Diagnosis of hypothyroidism and hyperthyroidism was ascertained from the medical record linkage system.44 Subjects were considered to have hypothyroidism if they had an International Classification of Disease (ICD) code for hypothyroidism (using ICD, Ninth Revision [ICD-9]45 or ICD, Eighth Revision, Adapted Codes for Hospitals [HICDA]46). The ICD-9 codes were 244, 244.0, 244.1, 244.2, 244.3, 244.8, 244.9, 243, and the HICDA codes were 02430240, 02440110, 02448111, 02449120, 02449130, 02440111, 02442110, 02442111, 02448110, 02449110, and 02441120. Clinical hypothyroidism was diagnosed as a medical record documentation of clinical hypothyroidism by treating physicians along with the confirmation of thyroid replacement therapy. Participants with a documented diagnosis of clinical hypothyroidism without documented thyroid replacement therapy were characterized as having clinically overt hypothyroidism if they had a TSH level of 10 mIU/L or higher with a free thyroxine level less than 1.01 ng/dL (to convert to picomoles per liter, multiply by 12.871).10 Participants were characterized as having subclinical hypothyroidism based on physician documentation in the medical record, a TSH level less than 10 mIU/L, free thyroxine level of 1.01 to 1.79 ng/dL, and no thyroxine replacement therapy. Participants with hyperthyroidism were excluded from the study; this was based on a physician’s diagnosis of hyperthyroidism in the medical record and an abnormally low TSH level. All thyroid tests were performed as per Mayo Clinic laboratory protocols.
Covariates ascertained by personal interview during the baseline evaluation included sex, age, years of education, depression, diabetes mellitus, hypertension, stroke or transient ischemic attack, and coronary artery disease (angina, myocardial infarction, and coronary revascularization or bypass graft). Self-reported different medical comorbidities were confirmed from the Mayo Clinic medical records linkage system.44 Depression was assessed during the interview of participants using the Beck Depression Inventory.47 Body mass index (calculated as weight in kilograms divided by height in meters squared) was measured at the baseline visit. Apolipoprotein E (APOE) genotyping was done for each participant using validated methods.48
Descriptive characteristics for categorical variables were summarized as frequencies, and significance differences were evaluated using a χ2 test. Continuous variables were summarized as median and interquartile range, and comparisons were made using the rank sum test. A multiple logistic regression model was used to examine the association of clinical and subclinical hypothyroidism with MCI. The association was modeled with and without the preidentified covariates of interest, and the model was stratified further according to sex and APOE ε4. We generated an overall model adjusted for age, years of education, sex, APOE ε4, depression, diabetes, hypertension, stroke, body mass index, and coronary artery disease and also examined interactions of sex and APOE ε4 with clinical and subclinical hypothyroidism. Linear regression models adjusted for age, years of education, sex, and APOE ε4 were also used to evaluate the association of hypothyroidism with the 4 cognitive domains (memory, language, visuospatial, and attention). All the calculated P values were unpaired and 2-tailed, and differences were considered statistically significant at P < .05. All analyses were performed using SAS, version 3 (SAS Institute, Inc).
A total of 2050 participants were evaluated in person by study personnel. Of these, 122 were excluded: 67 had dementia at baseline, 14 had incomplete assessments, and 41 did not provide authorization to use their medical records in research. Of the remaining 1928 individuals, 24 were excluded because of hyperthyroidism at the time of evaluation.
Of the 1904 people included in the analyses, 316 had MCI (58.5% men) and 1588 (793 [49.9%] of them men) had normal cognitive function. Of the 316 individuals with MCI, 229 were amnestic and 87 were nonamnestic. Participants with MCI were older than those with normal cognitive function (82.1 vs 79.6 years; P < .001), were less educated (13.0 vs 13.8 years of education; P < .001), and had a lower body mass index (27.1 vs 27.8; P = .03). In addition, participants with MCI had a higher frequency of APOE ε4 allele carriers compared with those with normal cognitive function (30.0% vs 21.9%; P = .003), with borderline to high frequency of comorbidities, including hypertension (83.5% vs 78.5%; P = .05), coronary artery disease (49.1% vs 40.3%; P = .005), diabetes mellitus (24.8% vs 12.3%; P = .05), stroke (19.9% vs 9.8%; P < .001), and depression (14.7% vs 8.0%; P = .001). A history of ever smoking was similar between the individuals with MCI and those with normal cognitive function (49.7% vs 49.1%; P = .90).
Of the 1904 included persons, 1450 had normal thyroid function, of whom 83.7% had normal cognitive function and 16.3% had MCI. Clinical hypothyroidism was identified in 313 individuals (82.8% with normal cognitive function and 17.2% with MCI), and 141 had subclinical hypothyroidism (82.3% with normal cognitive function and 17.7% with MCI). Most of the participants (96.5%) with clinical hypothyroidism were receiving thyroid replacement therapy, and those with subclinical hypothyroidism were not receiving thyroid replacement therapy. Demographic characteristics and distribution of different covariates between the 3 groups (clinical hypothyroidism, subclinical hypothyroidism, and normal thyroid function) are described in Table 1.
Compared with persons with normal thyroid function, clinical hypothyroidism was not associated with MCI in the model 1 adjusted for age at visit, sex, and educational level (odds ratio [OR], 1.09; 95% CI, 0.77-1.53). Even after adjusting the model for covariates (age, years of education, sex, APOE ε4, depression, diabetes, hypertension, stroke, body mass index, and coronary artery disease), we did not find a statistically significant association between MCI and clinical hypothyroidism (OR, 0.99; 95% CI, 0.66-1.48) (Table 2).
Similarly, there was no association of subclinical hypothyroidism with MCI in model 1 (OR, 1.03; 95% CI, 0.65-1.65) compared with normal thyroid function. There was also no association in model 2 (OR, 0.88; 95% CI, 0.38-2.03) after adjustment for covariates.
Because hypothyroidism is more frequent in women,49,50 we conducted a stratified analysis by sex to assess possible effect modification on the association between MCI and hypothyroidism. Table 2 presents the 2 models for the association between MCI and thyroid function in men and in women. None of the models showed significant associations of MCI with clinical or subclinical hypothyroidism. Stratified analysis by APOE ε4 also showed a nonsignificant association between MCI and the thyroid groups (Table 2). The association of amnestic MCI and nonamnestic MCI with clinical and subclinical hypothyroidism was also nonsignificant. Table 3 describes the associations of clinical and subclinical hypothyroidism with 4 cognitive domains after controlling for age, years of education, sex, and APOE ε4.
In this population-based cross-sectional study in elderly persons, we did not find any significant association of MCI with clinical and subclinical hypothyroidism after accounting for possible confounding factors and interactions. Our findings are consistent with those of previous studies that reported a lack of association between thyroid dysfunction and cognitive decline.9- 15,20- 24 Gussekloo et al10 found no association between thyroid status and cognitive performance in either cross-sectional or prospective study designs in a population-based cohort of individuals aged 85 years or older. Similarly, other investigators were unable to find any significant association of cognitive decline with subclinical hypothyroidism9- 15 and clinical hypothyroidism.20- 24 However, they did not specifically look for the association of hypothyroidism with MCI, a well-defined, earliest detectable clinical stage of cognitive impairment.
On the other hand, many studies have identified a positive association of cognitive decline with clinical hypothyroidism16- 18,51 and subclinical hypothyroidism.3,5- 7 However, unlike the present study, none of the previous studies evaluated the association of hypothyroidism with MCI.
Cognitive decline and thyroid dysfunction are common in the elderly,10 and a widely held view is that hypothyroidism is a reversible risk factor for cognitive impairment, even though several studies have shown no such association. Our population-based findings also argue against an association and suggest that neither clinical nor subclinical hypothyroidism is a risk factor for MCI. Similarly, we did not find any significant association with individual cognitive domains except for the borderline association of clinical hypothyroidism with reduced performance in the visuospatial skills domain; however, the clinical significance of this is unknown. This raises questions about the need for routine testing of thyroid function as a part of the diagnostic workup in patients with MCI . Because patients with dementia were excluded from our analysis, we are unable to comment on the association of clinical and subclinical hypothyroidism with dementia. We found no significant interaction of hypothyroidism (clinical and subclinical) with sex and APOE ε4.
Our study has several strengths. It was large and population based, representing an upper-Midwest population, and may be generalizable to other populations represented in our study or to the US white population.52 Because participants were randomly selected from the population, the risk of selection bias is reduced in comparison with studies that enrolled individuals from hospitals or referral settings. We validated the self-report of different comorbidities using the medical record system of the Rochester Epidemiology Project. The ascertainment of MCI was done using a comprehensive evaluation, and the diagnosis was made by a consensus process resulting in a reliable approach for the detection of MCI.26 Potential weaknesses of our study include the cross-sectional design, which prevents us from making causal inferences, and our inability to confirm that hypothyroidism preceded MCI.
In conclusion, we found that clinical and subclinical hypothyroidism are not associated with MCI in an elderly population. Our findings need to be validated in separate settings using the standard criteria for MCI and validated in a longitudinal study. This study contributes to the growing body of evidence that suggests that hypothyroidism is not associated with MCI.
Accepted for Publication: October 9, 2013.
Corresponding Author: Ajay K. Parsaik, MD, Department of Psychiatry and Behavior Sciences, The University of Texas Medical School, Behavioral Biomedical Sciences Building, 1941 East Rd, Room 3236, Houston, TX 77054 (firstname.lastname@example.org).
Published Online: December 30, 2013. doi:10.1001/jamaneurol.2013.5402.
Author Contributions: Dr Parsaik had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Parsaik, Singh, Pankratz.
Acquisition of data: Parsaik, Singh, Roberts, Edwards, Geda, Knopman.
Analysis and interpretation of data: Parsaik, Roberts, Pankratz, Edwards, Gharib, Boeve, Knopman, Petersen.
Drafting of the manuscript: Parsaik, Singh, Gharib.
Critical revision of the manuscript for important intellectual content: Parsaik, Singh, Roberts, Pankratz, Edwards, Geda, Boeve, Knopman, Petersen.
Statistical analysis: Singh, Roberts, Pankratz, Edwards.
Obtained funding: Roberts, Petersen.
Administrative, technical, or material support: Parsaik, Roberts, Boeve.
Study supervision: Roberts, Pankratz, Knopman.
Conflict of Interest Disclosures: Dr Boeve has served as an investigator for clinical trials sponsored by Cephalon, Inc, Allon Pharmaceuticals, and GE Healthcare. He receives royalties from the publication of a book entitled Behavioral Neurology of Dementia (Cambridge Medicine; 2009). He has received honoraria from the American Academy of Neurology, serves on the Scientific Advisory Board of the Tau Consortium, and receives research support from the National Institute on Aging (grants P50 AG016574, U01 AG006786, RO1 AG032306, and RO1 AG041797) and the Mangurian Foundation. No other disclosures were reported.
Funding/Support: The study was funded by National Institutes of Health–National Institute on Aging grants K01 AG028573 (principal investigator [PI]: Dr Roberts), P50 AG016574 (PI: Dr Petersen), and U01 AG006786 (PI: Dr Petersen); by the National Institutes of Health–National Institute of Mental Health grant K01 MH068351 (PI: Dr Geda); and by the Robert H. and Clarice Smith and Abigail van Buren Alzheimer’s Disease Research Program.
Role of the Sponsors: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: We thank the study participants and the Mayo Clinic Study of Aging team (coordinators, psychometrists, psychologists, program management team, and physicians) for their help in conducting this study.
Correction: This article was corrected on July 3, 2014, to fix the study design description in the Abstract.